Pharmaceuticals
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shin...
2025-10-13 12:38
2983
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14
* EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from bothChina's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). * EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is devel...
2025-10-13 08:47
2012
Ascletis Selects a Best-In-Class Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for Clinical Development
- In head-to-head non-human primate (NHP) studies, average observed half-life of ASC35 was approximately 14 days, 6-fold longer than tirzepatide, which supports once-monthly subcutaneous (SQ) dosing in humans. - In head-to-head NHP studies, drug exposures of ASC35 intravenous (I.V.) and SQ admin...
2025-10-13 08:10
2195
Reach Surgical's OMNIBOT Performs First Urology Robotic Telesurgeries in Latin America
Advancing regional collaboration and surgeon training in remote robotic-assisted surgery SINGAPORE, Oct. 13, 2025 /PRNewswire/ -- Reach Surgical, the Surgical Solutions division of Genesis MedTech, has facilitated the completion of two robotic telesurgeries using its OMNIBOT robotic-assisted sys...
2025-10-13 08:00
1980
C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
CHENGDU, China, Oct. 11, 2025 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner,Biokin Pharmaceutical, on receiving implied approval from theNational Medical Products Administration (NMPA) for the clinical trial application of [177Lu]-BL-ARC001 Injec...
2025-10-11 20:45
3378
Health in Your Hands? Asia's Top Health Experts Say 'Yes' and Reveal How
* Over 100 healthcare leaders from 11 countries/regions convene at APSMI Summit to advance consumer-led self-care in healthcare. * The Summit highlights the importance of empowering individuals with knowledge and tools to support resilient health systems. BALI, Indonesia, Oct. 10, 2025 /PRNew...
2025-10-10 14:43
2053
Renalys Announces Completion of Primary Endpoint Data Collection for Phase III Clinical Trial of Sparsentan for Iga Nephropathy in Japan
TOKYO, Oct. 10, 2025 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku,Tokyo; "Renalys") announced today that it has completed data collection for the primary endpoint in the Phase III clinical trial of sparsentan (development code: RE-021) for IgA nephropathy inJapan. The primary endp...
2025-10-10 14:00
1547
IHH Healthcare launches Global Incubator to fuel game-changing innovation
By enabling early-stage start-ups to bring breakthrough ideas to life, IHH is catalysing next-level care and driving lasting impact across the healthcare ecosystem. "Through this Global Incubator Programme, we are expanding our innovation drive to support early-stage healthcare innovators, empow...
2025-10-10 13:09
1926
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year. This to...
2025-10-10 08:30
1978
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
* EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) * Celltrion plans to enter the U.S. ophthalmology market to m...
2025-10-10 06:56
3409
POMDOCTOR LIMITED Announces Closing of Initial Public Offering
GUANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- POMDOCTOR LIMITED (Nasdaq: POM) (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases inChina, today announced the closing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shar...
2025-10-10 04:05
3318
Phase 3 Clinical Trial of HANSIZHUANG Plus Chemotherapy Meets Primary Endpoint in Neoadjuvant/Adjuvant Gastric Cancer, Greenlighting Early NDA Submission
* The phase 3 clinical trial of HANSIZHUANG for perioperative gastric cancer treatment met its EFS primary endpoint, supporting an early New Drug Application (NDA) submission * World-first regimen in gastric cancer that replaces adjuvant chemotherapy with mono-immunotherapy in the perioperati...
2025-10-09 20:50
6342
Samsung Biologics Introduces Optimized Manufacturing Framework, ExellenS™
* ExellenS TM applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed * ExellenS TM combines the company's commitment to operational excellence with its core manufacturing competencies, guided by standardization, simplification, and scalab...
2025-10-09 19:00
2670
Chance Pharma Announces Commercialization Agreement with Huadong Medicine for Innovative Respiratory Drug CXG87
HANGZHOU, China, Oct. 9, 2025 /PRNewswire/ -- Chance Pharmaceuticals ("Chance" or "Chance Pharma"), a clinical-stage biotechnology company dedicated to the research and development of innovative inhalation therapies, today announced that it has reached an exclusive commercialization agreement wit...
2025-10-09 17:27
2289
Herbalgy, the Pain Management Expert, Partners with Heroes in White to Champion a "Pain-Relieving Serenity" Lifestyle
Bringing the Wisdom of Traditional Chinese Medicine into Modern Living HONG KONG, Oct. 9, 2025 /PRNewswire/ -- Following the phenomenal success of TVB's widely acclaimed TV dramaHeroes in White—the top-rated series of 2025 with an audience of over 1.57 million and a rating of 24.2 points—Herbalgy...
2025-10-09 14:18
1819
Everest Medicines Announces Publication of Etrasimod's Asian Multicenter Phase III ENLIGHT UC study (ES101002) Results in The Lancet Gastroenterology & Hepatology
* The published study results are from the ENLIGHT UC study (ES101002), a multicenter, randomized, double-blind and placebo-controlled Phase III trial of etrasimod conducted acrossAsia. The study included a 12-week induction phase followed by a 40-week maintenance phase and represents the large...
2025-10-09 13:10
1978
C-Ray Therapeutics (Shanghai) Co., Ltd. Presents Breakthrough Clinical Data of Novel Targeted Alpha Therapy 225Ac-PSMA-CY313 at EANM 2025
BARCELONA, Spain, Oct. 8, 2025 /PRNewswire/ -- During the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM 2025), C-Ray Therapeutics (Shanghai) Co., Ltd. ("C-Ray Shanghai"), a company dedicated to the development of innovative targeted radiopharmaceuticals, announced pro...
2025-10-08 22:20
2308
POMDOCTOR LIMITED Announces Pricing of Initial Public Offering
GUANGZHOU, China, Oct. 8, 2025 /PRNewswire/ -- POMDOCTOR LIMITED (the "Company" or "POMDOCTOR"), a leading online medical services platform for chronic diseases inChina, today announced the pricing of its initial public offering (the "Offering") of 5,000,004 American Depositary Shares ("ADSs") at...
2025-10-08 20:00
2797
Hope Medicine Inc. Announces Successful Completion of a Global Phase 2 Study of a Potential First-in-Class Endometriosis Treatment
HMI-115 demonstrated statistically significant improvement in endometriosis pain The mean dysmenorrhea pain score was reduced by 42% The mean non-menstrual pelvic pain score was reduced by 52% Most of the patients had normal menstrual periods No typical peri-menopausal symptoms were reported Th...
2025-10-08 09:08
3083
New White Paper by APAC CVD Alliance and Deloitte Charts Path to Tackle Rising Heart Failure Burden in Asia-Pacific
* 32 million people in Asia-Pacific live with heart failure, and this number is rising fast. * New blueprint targets a 20% cut in hospitalisations and 15% boost in survival rates within 5 years. * Urgent call for early diagnosis, digital and community-based care, and sustainable financing t...
2025-10-08 09:00
2235
Week's Top Stories
Most Reposted
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
[Picked up by 309 media titles]
2026-07-30 10:45
J.P. Morgan Private Bank Earns Record 10 Accolades at The Asset Triple A Private Capital Awards 2026
[Picked up by 294 media titles]
2026-07-30 15:00KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
[Picked up by 292 media titles]
2026-07-30 09:12
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
[Picked up by 291 media titles]
2026-07-27 19:02
ADA acquires Algonomy, strengthening its intelligent growth platform for a fully agentic experience
[Picked up by 290 media titles]
2026-07-30 15:30
Most Read
Franchising & Licensing Asia 2026 Opens New Chapter Under MP, Strengthening Singapore's Position as Asia's Franchise and Licensing Hub
2026-07-30 10:45
8388
Association of Trade and Commerce Reinforces Commitment to Supporting Singapore Enterprises Through Global Growth at The Entrepreneur Singapore 2026
2026-07-31 21:45
7514
Articura Launches a New Chapter for Sovereign Healthcare AI in Indonesia
2026-07-27 19:02
7309
KC Global Media announces new travel series "AXN Ultimate Challenge: Sarawak"
2026-07-30 09:12
7184